'
The related resources bookmark allows you to jump directly to other pages on the site that contain information directly related to the topics you're currently exploring.
Related Resources for this page:
- Biological Pathways
- Therapeutic Targets
- Research Education
- Clinical Trials
- Future Directions
- Antibody-Drug conjugates
- HER Signaling
- Anti-HER3/EGFR MAb (MEHD7945A)
- Anti-PDL1 (MPDL3280A)
- Emerging therapeutic options
- Emerging therapeutic options
- High VEGF expression
- VEGF in bladder cancer
- MVD and progression
- Summary
- VEGF and MVD
- VEGF and prognosis
- VEGF and progression
- VEGF and progression in urothelial carcinoma
- VEGF in gastric cancer
- Regulation of VEGF expression
- Serum VEGF as a clinical marker
- Summary
- VEGF expression in gastric cancer
- VEGF, MVD, and metastases in gastric carcinoma
- VEGF and tumor progression in gastric cancer
- VEGF in multiple myeloma
- Summary
- VEGF expression in multiple myeloma
- VEGF pathways in multiple myeloma
- VEGF and prognosis in multiple myeloma
- Hypoxic tumor environment promotes angiogenesis
- VEGF in pancreatic cancer
- Summary
- VEGF expression and liver metastases
- VEGF and prognosis in pancreatic cancer
- VEGF and tumor progression in pancreatic cancer
- Bispecific Monoclonal Antibodies
- Glycoengineered Antibodies
- HER Signaling
- Anti-HER3/EGFR MAb (MEHD7945A)
- Emerging therapeutic options
- Emerging therapeutic options
- High VEGF expression
- VEGF in bladder cancer
- MVD and progression
- Summary
- VEGF and MVD
- VEGF and prognosis
- VEGF and progression
- VEGF and progression in urothelial carcinoma
- VEGF in gastric cancer
- Regulation of VEGF expression
- Serum VEGF as a clinical marker
- Summary
- VEGF expression in gastric cancer
- VEGF, MVD, and metastases in gastric carcinoma
- VEGF and tumor progression in gastric cancer
- VEGF in multiple myeloma
- Summary
- VEGF expression in multiple myeloma
- VEGF pathways in multiple myeloma
- VEGF and prognosis in multiple myeloma
- Hypoxic tumor environment promotes angiogenesis
- VEGF in pancreatic cancer
- Summary
- VEGF expression and liver metastases
- VEGF and prognosis in pancreatic cancer
- VEGF and tumor progression in pancreatic cancer
- Non-Antibody Biologics
- Apoptosis
- High VEGF expression
- VEGF in bladder cancer
- MVD and progression
- Summary
- VEGF and MVD
- VEGF and prognosis
- VEGF and progression
- VEGF and progression in urothelial carcinoma
- VEGF in gastric cancer
- Regulation of VEGF expression
- Serum VEGF as a clinical marker
- Summary
- VEGF expression in gastric cancer
- VEGF, MVD, and metastases in gastric carcinoma
- VEGF and tumor progression in gastric cancer
- VEGF in multiple myeloma
- Summary
- VEGF expression in multiple myeloma
- VEGF pathways in multiple myeloma
- VEGF and prognosis in multiple myeloma
- Hypoxic tumor environment promotes angiogenesis
- VEGF in pancreatic cancer
- Summary
- VEGF expression and liver metastases
- VEGF and prognosis in pancreatic cancer
- VEGF and tumor progression in pancreatic cancer
- What are the strategies for inhibiting the VEGF pathway?
- Targeted Small Molecules
- Apoptosis
- MAPK Signaling
- PI3K/Akt/mTOR Signaling
- Anti-HER3/EGFR MAb (MEHD7945A)
- Emerging therapeutic options
- Emerging therapeutic options
- Slide decks and videos
- High VEGF expression
- VEGF in bladder cancer
- MVD and progression
- Summary
- VEGF and MVD
- VEGF and prognosis
- VEGF and progression
- VEGF and progression in urothelial carcinoma
- VEGF in gastric cancer
- Regulation of VEGF expression
- Serum VEGF as a clinical marker
- Summary
- VEGF expression in gastric cancer
- VEGF, MVD, and metastases in gastric carcinoma
- VEGF and tumor progression in gastric cancer
- VEGF in multiple myeloma
- Summary
- VEGF expression in multiple myeloma
- VEGF pathways in multiple myeloma
- VEGF and prognosis in multiple myeloma
- Hypoxic tumor environment promotes angiogenesis
- VEGF in pancreatic cancer
- Summary
- VEGF expression and liver metastases
- VEGF and prognosis in pancreatic cancer
- VEGF and tumor progression in pancreatic cancer
- What are the strategies for inhibiting the VEGF pathway?
- Melanoma
- Traditional Monoclonal Antibodies
- Angiogenic Signaling
- B-cell Surface Proteins
- HER Signaling
- Parsatuzumab (Anti-EGFL7)
- Anti-HER3/EGFR MAb (MEHD7945A)
- Anti-PDL1 (MPDL3280A)
- Emerging therapeutic options
- Emerging therapeutic options
- Glossary
- Slide decks and videos
- High VEGF expression
- VEGF in bladder cancer
- MVD and progression
- Summary
- VEGF and MVD
- VEGF and prognosis
- VEGF and progression
- VEGF and progression in urothelial carcinoma
- VEGF in gastric cancer
- Regulation of VEGF expression
- Serum VEGF as a clinical marker
- Summary
- VEGF expression in gastric cancer
- VEGF, MVD, and metastases in gastric carcinoma
- VEGF and tumor progression in gastric cancer
- VEGF in multiple myeloma
- Summary
- VEGF expression in multiple myeloma
- VEGF pathways in multiple myeloma
- VEGF and prognosis in multiple myeloma
- Hypoxic tumor environment promotes angiogenesis
- VEGF in pancreatic cancer
- Summary
- VEGF expression and liver metastases
- VEGF and prognosis in pancreatic cancer
- VEGF and tumor progression in pancreatic cancer
- What are the strategies for inhibiting the VEGF pathway?
- Melanoma
- Antibody-Drug conjugates
Share
Glioblastoma
Disease Information
Genentech BioOncology is dedicated to advancing the science of glioblastoma therapy through comprehensive research programs and education. Glioblastomas usually form in astrocytes in the cerebral white matter.1
Glioblastoma Demographic Statistics
- In 2004–2007, an estimated 37,890 Americans were diagnosed with glioblastoma—16.7% of all reported brain tumors2
Glioblastoma Epidemiology
- Most brain tumors are not associated with known risk factors.1 However, risk factors include ionizing radiation exposure to the head and a family history of inherited conditions such as neurofibromatosis type 1 and Li-Fraumeni syndrome1,3
- The 5-year survival rate for patients with glioblastoma is 2.9%4
- The median survival time for glioblastoma is limited to approximately 10 to 15 months5
Glioblastoma Symptoms
Symptoms of glioblastoma include headache; nausea; vomiting; blurred vision; balance problems; drowsiness; seizure; hemiparesis; and progressive memory, personality, or neurologic deficits.1,3
Other links to glioblastoma disease information
These links give a sampling of other sites offering information on glioblastoma, which you may find useful in your practice.
- National Cancer Institute at National Institutes of Health, Brain Tumor
- ASCO Cancer Portals - Head & Neck Cancers
- Cancer Facts & Figures
Unless otherwise indicated, Genentech, Inc. is neither affiliated with nor endorses any of the organizations listed.
References:
- 1.
- American Cancer Society. Brain and spinal cord tumors in adults. www.cancer.org/Cancer/BrainCNSTumorsinAdults/DetailedGuide/brain-and-spinal-cord-tumors-in-adults-what-is-cancer. Accessed April 14, 2011.
- 2.
- CBTRUS (2011). CBTRUS Statistical Report: Primary Brain and Central Nervous System Tumors Diagnosed in the United States in 2004-2007. Source: Central Brain Tumor Registry of the United States, Hinsdale, IL. Web site: www.cbtrus.org. Accessed April 13, 2011.
- 3.
- US Department of Health and Human Services. National Cancer Institute. What you need to know about™ brain tumors. Accessed April 14, 2011.
- 4.
- Barnholtz-Sloan JS, Sloan AE, Schwartz AG. Cancer of the brain and other central nervous system. In: SEER Survival Monograph. National Cancer Institute. www.seer.cancer.gov/publications/survival/surv_brain.pdf. Accessed April 14, 2011.
- 5.
- Nieder C, Grosu AL, Astner S, Molls M. Treatment of unresectable glioblastoma multiforme. Anticancer Res. 2005;25:4605-4610. PMID: 16334150